Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in
hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has …

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the
signaling of interleukin (IL)-4 and-13. Several other chronic skin conditions share …

Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T‐cell (Th2)‐immune response in AA …

Alopecia areata (AA) is a chronic, immune‐mediated disease characterized by acute or
chronic non‐scarring hair loss, with a heterogeneity in clinical manifestations ranging from …

Alopecia areata (AA) is characterized by common non-scarring alopecia due to autoimmune
disorders. To date, the specific pathogenesis underlying AA remains unknown. Thus, AA …

Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by
recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places …

Background Observational studies have suggested the association between atopic
dermatitis (AD) and the risks of autoimmune diseases. It is still unclear, however, whether or …

Background The mechanisms driving alopecia areata (AA) are still unclear, hindering
development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides …

Management options for moderate‐to‐severe alopecia areata (AA) are limited owing to a
lack of safe and effective treatments suitable for long‐term use. However, newer agents …

Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis J …